Stayble Therapeutics AB
559024-8372ActiveDeveloping an injection treatment for pain caused by disc herniation.
Clinical Pharmaceutical Company / Biotechnology Firmstaybletherapeutics.com
Yleiskatsaus
- 5–9
- Työntekijät
- 300–399t SEK
- Liikevaihto
- 2015
- Perustettu
Avainpäättäjät
Andreas Gerward
Chief Executive Officer
@stayble.se+46730XXXXXX
Anders Lehmann
Chief Scientific Officer
@stayble.se
Erik Kullgren
Chief Financial Officer
Gunnar Fernström
Board Member
+4 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Stayble Therapeutics is a clinical pharmaceutical company focused on developing innovative treatments for debilitating leg pain caused by Lumbar Disc Herniation (LDH). Their core product candidate, STA363, is a patented, disease-modifying treatment administered via a single injection. This therapy a...